Anti-Mouse CD70 - APC

Leinco Technologies
Product Code: LEI-C2405
Product Group: Primary Antibodies
CodeSizePrice
LEI-C2405-25ug25 ug£289.00
Quantity:
LEI-C2405-100ug100 ug£492.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rat
Antibody Isotype: IgG2b
Antibody Clonality: Monoclonal
Antibody Clone: FR70
Regulatory Status: RUO
Target Species: Mouse
Applications:
  • Flow Cytometry
  • Functional Study
Shipping:
2-8°C
Storage:
This APC conjugate is stable when stored at 2-8°C. Do not freeze.

Further Information

Antigen Distribution:
Mouse CD70 is transiently expressed on the surfaces of antigen-activated B and T cells, natural killer cells, and mature dendritic cells. CD70 is also aberrantly expressed on malignant cancer cells.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
Allophycocyanin (APC)
Format:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
BALB/c mouse B lymphoma A20.J2
Long Description:
CD70, a type II transmembrane glycoprotein of the TNF family with cytokine activity, is the ligand for the CD27 receptor1. Mouse CD70 (mCD70) has a potent co-stimulatory effect on T cell proliferation1 and acts as an immune-checkpoint2. In mouse, but not in humans, the CD70-CD27 axis mediates a negative feedback system that enables the immune system to modulate hematopoiesis2. Additionally, CD70-CD27 interactions are important to the formation of memory and plasma B cells. Immunotherapies that aim to eradicate tumor cells by targeting CD70 overexpression are being developed2. FR70 inhibits mCD70 binding to mCD27-Ig, a recombinant soluble form of mCD271, as well as to mCD27 in vitro3,4 and in vivo5. FR70 was produced by immunizing an F344/DuCrj rat with A20 cells and fusing the splenocytes with P3U1 cells to create hybridoma lines1. HAT selection was performed, and FR70 was identified by its strong reactivity against mCD70-BHK21 cells. Blocking with FR70 can prolong graft acceptance6,7. When mouse cardiac allogenic graft recipients are treated with FR70, tolerogenic dendritic cells and T regulatory cells are induced, resulting in decreased cytotoxic T lymphocyte proliferation as well as long-term graft acceptance6. Blocking with FR70 also prolongs mouse corneal graft survival7.
NCBI Gene:
21948
Target:
CD70

References

1. Oshima H, Nakano H, Nohara C, et al. Int Immunol. 10(4):517-526. 1998. 2. Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. J Exp Clin Cancer Res. 41(1):12. 2022. 3. Mahmud SA, Manlove LS, Schmitz HM, et al. Nat Immunol. 15(5):473-481. 2014. 4. Kuka M, Munitic I, Giardino Torchia ML, et al. J Immunol. 191(5):2282-2289. 2013. 5. Ballesteros-Tato A, Le?n B, Lee BO, et al. Immunity. 41(1):127-140. 2014. 6. Zhao J, Que W, Du X, et al. Front Immunol. 11:555996. 2021. 7. Narimatsu A, Hattori T, Usui Y, et al. Exp Eye Res. 199:108190. 2020. 8. Wensveen FM, Unger PP, Kragten NA, et al. J Immunol. 188(9):4256-4267. 2012. 9. Tewalt EF, Cohen JN, Rouhani SJ, et al. Blood. 120(24):4772-4782. 2012. 10. Ho PC, Meeth KM, Tsui YC, et al. Cancer Res. 74(12):3205-3217. 2014.